AR053047A1 - 1h-quinazolin-2,4-dionas como ligandos del receptor ampa - Google Patents

1h-quinazolin-2,4-dionas como ligandos del receptor ampa

Info

Publication number
AR053047A1
AR053047A1 ARP060101392A ARP060101392A AR053047A1 AR 053047 A1 AR053047 A1 AR 053047A1 AR P060101392 A ARP060101392 A AR P060101392A AR P060101392 A ARP060101392 A AR P060101392A AR 053047 A1 AR053047 A1 AR 053047A1
Authority
AR
Argentina
Prior art keywords
amino
alkyl
substituents
alkoxy
dialkyl
Prior art date
Application number
ARP060101392A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34610935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR053047A1 publication Critical patent/AR053047A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/66—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/18—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups bound to carbon atoms of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00—Derivatives of isocyanic acid
    • C07C265/12—Derivatives of isocyanic acid having isocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Dental Preparations (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

Su preparacion, a su uso como productos farmacéuticos, y a composiciones farmacéuticas que las contienen. Además, se dan a conocer intermediarios para la fabricacion de los compuestos de la formula (1), y combinaciones que comprenden a los compuestos de la formula (1). Reivindicacion 1: Compuestos de la formula (1), en donde: R1 representa CF3, CHF2, CH2F, CH2F, CH3CHF-, CH3CF2-, etilo, o iso-propilo; y R2 representa alquilo sustituido por uno o más sustituyentes, seleccionándose los sustituyentes a partir del grupo que consiste en halogeno, nitro, acilo, hidroxilo, oxo, (=O), alcoxilo, cicloalcoxilo, aciloxilo, alcoxi-carboniloxilo, amino, alquil-amino, dialquil-amino, formilo, acil-amino, alcoxi-carbonil-amino; o R2 representa heterociclil-alquilo sustituido por uno o más sustituyentes, seleccionándose los sustituyentes a partir del grupo que consiste en halogeno, nitro, ciano, hidroxilo, alcoxilo, alquil-carboniloxilo, alcoxi-carboniloxilo, amino, alquil-amino, dialquil- amino, alcoxi-carbonil-amino; o R2 representa fenilo sustituido por uno o más sustituyentes, seleccionándose los sustituyente a partir del grupo que consiste en ciano, hidroxilo, alcandiilo, alquendiilo, alcoxilo, hidroxi-alquilo, formilo, alquil- carbonilo, alcoxi-carbonilo, alquil-carboniloxilo, alcoxi-carboniloxilo, amino, alquil-amino, dialquil-amino, amino-alquilo, alquil-amino-alquilo, dialquil-amino-alquilo, alcoxi-carbonil-amino; o R2 representa heterociclilo opcionalmente sustituido por uno o más sustituyentes, seleccionándose los sustituyentes a partir del grupo que consiste en halogeno, hidroxilo, amino, nitro, ciano, alquilo, hidroxi-alquilo, alcoxi-alquilo, amino-alquilo, alquil-amino-alquilo, dialquil-amino-alquilo, acilo, alcoxilo, aciloxilo, alcoxi-carboniloxilo, amino, alquil-amino, dialquil-amino, acil-amino, alcoxi-carbonil-amino, y en donde el heterociclo está enlazado al anillo de fenilo por un átomo de carbono; y sus sales.
ARP060101392A 2005-04-11 2006-04-07 1h-quinazolin-2,4-dionas como ligandos del receptor ampa AR053047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0507298.8A GB0507298D0 (en) 2005-04-11 2005-04-11 Organic compounds

Publications (1)

Publication Number Publication Date
AR053047A1 true AR053047A1 (es) 2007-04-18

Family

ID=34610935

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101392A AR053047A1 (es) 2005-04-11 2006-04-07 1h-quinazolin-2,4-dionas como ligandos del receptor ampa

Country Status (36)

Country Link
US (4) US7655666B2 (es)
EP (4) EP2476671A1 (es)
JP (2) JP4898783B2 (es)
KR (2) KR100990783B1 (es)
CN (2) CN101155789B (es)
AR (1) AR053047A1 (es)
AU (2) AU2006233639B2 (es)
BR (1) BRPI0608617A2 (es)
CA (1) CA2601986C (es)
CY (2) CY1113573T1 (es)
DK (2) DK2468732T3 (es)
EC (1) ECSP12007795A (es)
ES (2) ES2524316T3 (es)
GB (1) GB0507298D0 (es)
GT (2) GT200600144AA (es)
HK (1) HK1113790A1 (es)
HR (2) HRP20120867T1 (es)
IL (2) IL185544A (es)
IN (1) IN2012DN00785A (es)
JO (1) JO2770B1 (es)
MA (1) MA29411B1 (es)
MX (1) MX2007012592A (es)
MY (2) MY149070A (es)
NO (1) NO20075749L (es)
NZ (2) NZ560964A (es)
PE (2) PE20061306A1 (es)
PL (2) PL2468732T3 (es)
PT (2) PT2468732E (es)
RU (2) RU2435760C2 (es)
SA (2) SA06270089B1 (es)
SG (1) SG177182A1 (es)
SI (2) SI1871749T1 (es)
TN (1) TNSN07383A1 (es)
TW (2) TWI385158B (es)
WO (1) WO2006108591A1 (es)
ZA (2) ZA200807421B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
TW200934497A (en) * 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
EP2337566A1 (en) * 2008-10-22 2011-06-29 Novartis AG Combinations for the treatment of migraine
BR112012001258A2 (pt) * 2009-07-23 2016-02-10 Novartis Ag 1h-quinazolina-2,4-dionas para uso no tratamento da lipofuscinose ceroide neuronal
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
AU2010336510B2 (en) * 2009-12-22 2014-06-26 Novartis Ag Formulation comprising 1 H - quinazoline - 2, 4 - dione AMPA receptor antagonists, in the form of immediate release tablets and preparation thereof
CN102906085A (zh) * 2010-05-20 2013-01-30 诺瓦提斯公司 2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基-磺酰胺衍生物
AU2011268865A1 (en) * 2010-06-24 2013-01-31 Novartis Ag Use of 1H-quinazoline-2,4-diones
CN103080102B (zh) 2010-07-09 2016-08-24 拜耳知识产权有限责任公司 作为杀虫剂的邻氨基苯甲酰胺衍生物
WO2012101058A1 (en) 2011-01-24 2012-08-02 Novartis Ag 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
IN2014DN01791A (es) 2011-09-07 2015-05-15 Novartis Ag
WO2014042176A1 (ja) * 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
TWI726544B (zh) 2013-12-24 2021-05-01 美商必治妥美雅史谷比公司 作為抗癌劑之新穎三環化合物
WO2016023826A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Quinazoline-2,4(1h,3h)-dione derivatives as trcp5 modulators for the treatment of neuropsychiatry disorders
WO2019217449A1 (en) 2018-05-10 2019-11-14 Zoetis Services Llc Endoparasitic depsipeptides

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US535475A (en) 1895-03-12 Governor
GB281309A (en) 1926-11-27 1928-03-29 Inventia Patent Verwert Ges Improvements in or relating to brushing machines having replaceable brush members
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2838519A (en) 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US3310553A (en) 1962-09-25 1967-03-21 Pfizer & Co C Alkylated thioxathenesulfonamides
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3637661A (en) 1970-03-04 1972-01-25 Ciba Geigy Corp 10-hydroxy-10 11-dihydro-dibenzazepine derivative
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
FI834666A (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
WO1988001270A1 (en) * 1986-08-21 1988-02-25 Pfizer Inc. Pyridopyrimidinediones
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5122522A (en) 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
CA2002182C (en) 1989-11-03 2000-06-13 Richard J. Wurtman Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use
IE913473A1 (en) * 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
HU219778B (hu) 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
EP0539805B1 (de) 1991-10-31 1997-09-03 ASTA Medica Aktiengesellschaft Neue Phthalazine, die in 1-Stellung eine Ether-Gruppierung enthalten und Verfahren zu deren Herstellung
GB9125485D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
AU4090093A (en) 1992-05-29 1993-12-30 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
US5597922A (en) 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
EP0840610A1 (en) 1995-07-14 1998-05-13 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
US5773434A (en) 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
GB9604943D0 (en) 1996-03-08 1996-05-08 Chiroscience Ltd Resolution
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US6030968A (en) 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
ES2264171T3 (es) 1996-10-24 2006-12-16 Novartis Ag Acidos aminoalcanofosfonicos sustituidos.
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
US6380204B1 (en) 1997-02-28 2002-04-30 Pfizer Inc Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
TW526195B (en) 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
GB9721497D0 (en) 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
DE69838485T2 (de) 1997-10-09 2008-06-26 Emory University Verfahren und vorrichtung zur transdermalen verabreichung von lithium
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
RU2214405C2 (ru) * 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
US6100401A (en) 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
EP1002535A1 (en) 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US6162919A (en) 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
JP2000309585A (ja) * 1999-02-26 2000-11-07 Kyorin Pharmaceut Co Ltd ６−置換ヘテロキノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
EA005585B1 (ru) * 2000-01-24 2005-04-28 Уорнер-Ламберт Компани 3-аминохиназолин-2,4-дионовые антибактериальные агенты
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
JP2005500833A (ja) 2001-06-25 2005-01-13 ブアズーボ・アンパルトセルスカブ 腫瘍学薬物の革新
US20030144234A1 (en) 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US20060264508A1 (en) 2001-10-16 2006-11-23 Stone Richard A Modulation of ocular growth and myopia by gaba drugs
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
KR20040097236A (ko) 2002-03-29 2004-11-17 야마노우치세이야쿠 가부시키가이샤 신경 교아종 치료제
JP4175846B2 (ja) 2002-08-08 2008-11-05 独立行政法人科学技術振興機構 Ａｍｐａ型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制
AU2003270446A1 (en) 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
JP2006511587A (ja) 2002-12-20 2006-04-06 ミジェニックス コーポレイション アデニンヌクレオチドトランスロカーゼ（ａｎｔ）リガンドならびにそれに関連する組成物および方法
WO2004058704A2 (en) 2002-12-23 2004-07-15 Icagen, Inc. Quinazolinones as potassium channel modulators
WO2004067524A1 (en) 2003-01-29 2004-08-12 Pharmagene Laboratories Limited Ep4 receptor antagonists
EP1667685B1 (en) 2003-09-23 2012-03-14 Merck Sharp & Dohme Corp. Quinazoline potassium channel inhibitors
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP2463278A1 (en) 2012-06-13
PE20091366A1 (es) 2009-09-21
AU2011200888A1 (en) 2011-03-24
JO2770B1 (en) 2014-03-15
KR20070110919A (ko) 2007-11-20
EP2468732A1 (en) 2012-06-27
GB0507298D0 (en) 2005-05-18
PT2468732E (pt) 2014-11-25
HRP20141116T1 (hr) 2015-01-30
US8012988B2 (en) 2011-09-06
RU2509764C2 (ru) 2014-03-20
NO20075749L (no) 2008-01-11
BRPI0608617A2 (pt) 2010-01-19
GT200600144AA (es) 2011-12-13
IN2012DN00785A (es) 2015-06-26
TWI385158B (zh) 2013-02-11
RU2435760C2 (ru) 2011-12-10
DK1871749T3 (da) 2012-11-12
TNSN07383A1 (en) 2009-03-17
TW201304781A (zh) 2013-02-01
SI1871749T1 (sl) 2012-12-31
PT1871749E (pt) 2012-11-14
SG177182A1 (en) 2012-01-30
RU2007141566A (ru) 2009-05-20
ZA200707111B (en) 2010-05-26
CA2601986C (en) 2015-03-31
HRP20120867T1 (hr) 2012-11-30
EP1871749A1 (en) 2008-01-02
TWI440461B (zh) 2014-06-11
CN101155789A (zh) 2008-04-02
JP4898783B2 (ja) 2012-03-21
PL2468732T3 (pl) 2015-02-27
PE20061306A1 (es) 2006-12-23
US7655666B2 (en) 2010-02-02
EP2468732B1 (en) 2014-08-20
IL185544A0 (en) 2008-01-06
HK1113790A1 (en) 2008-10-17
ZA200807421B (en) 2010-04-28
JP5525500B2 (ja) 2014-06-18
NZ590463A (en) 2012-05-25
NZ560964A (en) 2011-02-25
ES2524316T3 (es) 2014-12-05
RU2011131276A (ru) 2013-02-10
IL220682A0 (en) 2012-08-30
AU2006233639B2 (en) 2010-12-09
KR20090127944A (ko) 2009-12-14
JP2012036203A (ja) 2012-02-23
SA06270089B1 (ar) 2010-03-20
ES2392542T3 (es) 2012-12-11
KR101162827B1 (ko) 2012-07-05
MY142474A (en) 2010-11-30
MY149070A (en) 2013-07-15
TW200716568A (en) 2007-05-01
IL185544A (en) 2014-03-31
CN101155789B (zh) 2012-08-29
SI2468732T1 (sl) 2014-12-31
US20130296332A1 (en) 2013-11-07
CN102807531A (zh) 2012-12-05
CA2601986A1 (en) 2006-10-19
AU2006233639A1 (en) 2006-10-19
US20110294818A1 (en) 2011-12-01
MA29411B1 (fr) 2008-04-01
US20080153836A1 (en) 2008-06-26
JP2008536839A (ja) 2008-09-11
ECSP12007795A (es) 2013-01-31
GT200600144A (es) 2006-12-18
WO2006108591A1 (en) 2006-10-19
IL220682A (en) 2014-03-31
CY1115767T1 (el) 2017-01-25
EP2476671A1 (en) 2012-07-18
EP1871749B1 (en) 2012-08-01
SA109300363B1 (ar) 2013-02-06
AU2011200888B2 (en) 2012-02-02
KR100990783B1 (ko) 2010-10-29
DK2468732T3 (da) 2014-11-10
MX2007012592A (es) 2007-11-16
PL1871749T3 (pl) 2013-01-31
US20100144747A1 (en) 2010-06-10
US8513268B2 (en) 2013-08-20
CY1113573T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
AR053047A1 (es) 1h-quinazolin-2,4-dionas como ligandos del receptor ampa
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
AR060768A1 (es) Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.
AR073138A1 (es) Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol
AR072791A1 (es) DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
AR082562A1 (es) Derivados de isoxazolina como agentes antiparasitarios
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20080263A1 (es) Compuestos de pirrolo-pirimidina y sus usos
AR049577A1 (es) Derivados de hidantoina, procesos para su preparacion, composiciones y su uso
CR11623A (es) Compuestos
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR060609A1 (es) Compuestos inhibidores de proteinquinasas c-fms.
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR066020A1 (es) Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1.
AR044078A1 (es) Dihidroquinazolinas sustituidas
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
CO6230982A2 (es) Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen
AR078722A1 (es) Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol

Legal Events

Date Code Title Description
FB Suspension of granting procedure